See more : PagerDuty, Inc. (PD) Income Statement Analysis – Financial Results
Complete financial analysis of BenevolentAI S.A. (BAI.AS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BenevolentAI S.A., a leading company in the Biotechnology industry within the Healthcare sector.
- The Siam Cement Public Company Limited (SCVPY) Income Statement Analysis – Financial Results
- PT Astra Agro Lestari Tbk (AALI.JK) Income Statement Analysis – Financial Results
- New Residential Investment Corp. (NRZ-PB) Income Statement Analysis – Financial Results
- Kolte-Patil Developers Limited (KOLTEPATIL.BO) Income Statement Analysis – Financial Results
- Vogo SA (ALVGO.PA) Income Statement Analysis – Financial Results
BenevolentAI S.A. (BAI.AS)
About BenevolentAI S.A.
BenevolentAI S.A. operates as a clinical-stage AI-enabled drug discovery and development company. Its BenevolentAI platform powers in-house drug pipeline of drug programs. The company's therapeutic areas, include atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral, oncology, parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. It has a collaboration with AstraZeneca to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 7.33M | 10.56M | 4.63M | 6.91M | 4.64M | 6.83M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 7.33M | 10.56M | 4.63M | 6.91M | 4.64M | 6.83M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 60.78M | 65.09M | 47.09M | 72.46M | 63.90M | 39.85M |
| General & Administrative | 22.41M | 31.99M | 24.64M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.41M | 31.99M | 24.64M | 0.00 | 0.00 | 0.00 |
| Other Expenses | 1.72M | 166.00K | 90.00K | 179.00K | 21.00K | 412.00K |
| Operating Expenses | 84.90M | 207.76M | 101.96M | 72.46M | 63.90M | 39.85M |
| Cost & Expenses | 84.90M | 207.76M | 101.96M | 72.46M | 63.90M | 39.85M |
| Interest Income | 3.86M | 1.55M | 56.00K | 279.00K | 143.00K | 60.00K |
| Interest Expense | 326.00K | 497.00K | 448.00K | 551.00K | 590.00K | 0.00 |
| Depreciation & Amortization | 2.88M | 3.06M | 2.94M | 2.90M | 4.39M | 748.00K |
| EBITDA | -69.44M | -192.47M | -118.32M | -62.20M | -54.71M | -31.86M |
| EBITDA Ratio | -947.27% | -1,822.64% | -1,806.29% | -900.49% | -1,178.75% | -472.81% |
| Operating Income | -77.57M | -197.03M | -100.15M | -65.37M | -59.24M | -32.61M |
| Operating Income Ratio | -1,058.15% | -1,865.85% | -2,165.43% | -946.45% | -1,276.38% | -477.73% |
| Total Other Income/Expenses | 4.92M | 17.18M | -21.56M | -272.00K | -447.00K | -412.00K |
| Income Before Tax | -72.65M | -179.85M | -100.54M | -65.64M | -59.68M | -33.02M |
| Income Before Tax Ratio | -991.00% | -1,703.14% | -2,173.90% | -950.38% | -1,286.02% | -483.77% |
| Income Tax Expense | -9.33M | -15.92M | -14.06M | -10.28M | -11.25M | -6.14M |
| Net Income | -63.32M | -163.93M | -86.48M | -55.36M | -48.43M | -26.88M |
| Net Income Ratio | -863.69% | -1,552.35% | -1,869.92% | -801.56% | -1,043.53% | -393.79% |
| EPS | -0.58 | -1.50 | -0.60 | -0.38 | -0.33 | -0.19 |
| EPS Diluted | -0.58 | -1.50 | -0.60 | -0.38 | -0.33 | -0.19 |
| Weighted Avg Shares Out | 109.11M | 109.11M | 145.13M | 145.13M | 145.13M | 145.13M |
| Weighted Avg Shares Out (Dil) | 109.11M | 109.11M | 145.13M | 145.13M | 145.13M | 145.13M |
Source: https://incomestatements.info
Category: Stock Reports